Table 4 Patient characteristics in “IRT” vs. “NIRT” groups.

From: Impact of sentinel lymph-node biopsy and FDG-PET in staging and radiation treatment of anal cancer patients

 

All patients (%)

Inguinal RT “IRT (%)

No inguinal “NIRT” (%)

Patients

80 (100)

54 (68)

26 (32)

Male

32 (40)

22 (41)

10 (38)

Female

48 (60)

32 (59)

16 (62)

Localization

Anal canal

56 (70)

37 (68)

19 (73)

Anal canal + rectal

12 (15)

8 (15)

4 (15)

Anal canal + margin

12 (15)

9 (17)

3 (12)

T1

14 (17)

8 (15)

6 (23)

T2

30 (38)

17 (32)

13 (50)

T3

24 (30)

18 (33)

6 (23)

T4

12 (15)

11 (20)

1 (4)

N0

29 (36)

15 (28)

14 (54)

N1

17 (21)

11 (20)

6 (23)

N2

14 (18)

12 (22)

2 (8)

N3

20 (25)

16 (30)

4 (15)

M0

73 (91)

48 (89)

25 (96)

M1

7 (9)

6 (11)

1 (4)

Positive PET/negative PET

0/49

18/30

2/19

Positive SLNB/negative SLBN

12/34

12/13

0/21

3DCRT

24 (30)

14 (26%)

10 (39)

Tomotherapy

18 (23)

14 (26%)

4 (15)

VMAT

38 (47)

26 (48)

12 (46)

  1. PET: positron emission tomography; SLBN: sentinel lymph-node biopsy; TP: true positive; TN: true negative; FP: false positive; FN: false negative; VMAT: volumetric modulated arc therapy; IRT: inguinal RT; NIRT: non inguinal RT.
Back to article page